In The News
Clyde & Co sued by insurers over indemnity advice
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
Law firm report clears WiseTech founder Richard White of misconduct
Second judge has rosier view of claims in class action over $85M development
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Russells partner accused of bullying told lawyer she was ‘very negative’
‘Our integrations are on track’: Class action flags WiseTech response to short seller report
Cornwalls hits back at $4.8M negligence suit by former client
Top silk to join NSW Supreme Court
NAB accused of rescinding job offer to pregnant employee
Please login to bookmarkClose

Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au